MEF2D

Across TCGA pan-cancer cohorts, MEF2D mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MEF2D data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MEF2D mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MEF2D expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, LSCC, and GBM are the cancer types where MEF2D mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.836	0.447	.005	26	view →
LSCC	DFS	Quartile	II,III,IV	0.388	0.882	.001	17	view →
GBM	OS	Quartile	All	0.702	0.404	.002	6	view →
PDAC	DFS	Median	III,IV	0.863	0.450	.018	6	view →
LUAD	DFS	Quartile	II,III,IV	0.321	0.628	.048	2	view →
HNSC	DFS	Quartile	III,IV	0.469	0.773	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MEF2D–CCRCC (DFS)

Open the CCRCC breakdown →